Browse ZBTB16

Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus, Nuclear body
Domain PF00651 BTB/POZ domain
Function

Acts as a transcriptional repressor (PubMed:24359566). May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:14528312).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0001865 NK T cell differentiation
GO:0002062 chondrocyte differentiation
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0003002 regionalization
GO:0007159 leukocyte cell-cell adhesion
GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007389 pattern specification process
GO:0008356 asymmetric cell division
GO:0009880 embryonic pattern specification
GO:0009952 anterior/posterior pattern specification
GO:0017145 stem cell division
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030217 T cell differentiation
GO:0030278 regulation of ossification
GO:0030326 embryonic limb morphogenesis
GO:0032330 regulation of chondrocyte differentiation
GO:0032332 positive regulation of chondrocyte differentiation
GO:0034504 protein localization to nucleus
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035116 embryonic hindlimb morphogenesis
GO:0035136 forelimb morphogenesis
GO:0035137 hindlimb morphogenesis
GO:0042078 germ-line stem cell division
GO:0042110 T cell activation
GO:0042733 embryonic digit morphogenesis
GO:0045444 fat cell differentiation
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045600 positive regulation of fat cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045778 positive regulation of ossification
GO:0045785 positive regulation of cell adhesion
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0048133 male germ-line stem cell asymmetric division
GO:0048232 male gamete generation
GO:0048736 appendage development
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051136 regulation of NK T cell differentiation
GO:0051138 positive regulation of NK T cell differentiation
GO:0051216 cartilage development
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0060173 limb development
GO:0061035 regulation of cartilage development
GO:0061036 positive regulation of cartilage development
GO:0061448 connective tissue development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0072001 renal system development
GO:0098722 asymmetric stem cell division
GO:0098728 germline stem cell asymmetric division
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
Molecular Function GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001206 transcriptional repressor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0008022 protein C-terminus binding
GO:0035326 enhancer binding
Cellular Component GO:0016604 nuclear body
GO:0016605 PML body
GO:0016607 nuclear speck
GO:0017053 transcriptional repressor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZBTB16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ZBTB16 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24550295MelanomaPromote immunity (T cell function)Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response. Importantly, CpG-activated type II NKT cells contribute to the antitumor effect of CpG in the B16 melanoma model.
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZBTB16 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZBTB16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1840.849
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4640.852
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.170.956
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2190.752
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3740.747
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.210.244
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0380.971
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9030.497
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6680.0212
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ZBTB16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZBTB16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZBTB16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZBTB16.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZBTB16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZBTB16 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZBTB16 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZBTB16
Namezinc finger and BTB domain containing 16
Aliases PLZF; promyelocytic leukaemia zinc finger; ZNF145; zinc finger protein 145 (Kruppel-like, expressed in promy ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZBTB16 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.